ARTICLE | Company News
Neovacs, Chong Kun Dang deal
January 11, 2016 8:00 AM UTC
Neovacs granted Chong Kun Dang exclusive rights to develop and commercialize IFNalpha-Kinoid in South Korea to treat lupus and dermatomyositis. Chong Kun Dang will be responsible for registration of the immunotherapy against interferon (IFN) alpha. The product is in Phase IIb testing; Neovacs expects the product to launch by early 2018. ...